Evidence map›Paper›PMID 40735350›Full record

ArticleBlood neoplasia2025

Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408.

Frederique St-Pierre, Stephen M Broski, Zequn Sun, Masha Kocherginsky, Betsy LaPlant, Matthew J Maurer, Andrew Quon, Lucia Baratto, Hatice Savas, Lale Kostakoglu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Frederique St-PierreDivision of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
Stephen M BroskiDivision of Nuclear Radiology, Department of Radiology, Mayo Clinic, Rochester, MN.
Zequn SunDivision of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
Masha KocherginskyDivision of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
Betsy LaPlantDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
Matthew J MaurerDivision of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
Andrew QuonDivision of Nuclear Radiology, Department of Radiology, University of California Los Angeles, Los Angeles, CA.
Lucia BarattoDepartment of Radiology, Stanford University, Stanford, CA.
Hatice SavasDivision of Nuclear Medicine, Department of Radiology, Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
Lale KostakogluDepartment of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA.
Jane N WinterDivision of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.
Thomas E WitzigDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
Brad KahlDivision of Oncology, Department of Medicine, Washington University School of Medicine and Siteman Cancer Center, St Louis, MO.
Andrew M EvensDivision Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.
Leo I GordonDivision of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.

Funding

Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)UG1CA232760 · NCI · MAYO CLINIC ROCHESTER · PI Judy Caroline Boughey, Aaron Scott Mansfield · 2019 to 2026
$8.5M
NCI NIH HHS U10 CA180820NCI NIH HHS UG1 CA232760
6 · The paper itself

Abstract

Parameters detected by positron emission tomography (PET) are not included in the usual predictive indices for follicular lymphoma (FL). Data are lacking regarding PET extranodal (EN) factors that predict outcomes in FL. PET scans from 258 patients with untreated grade 1 to 3A FL included in the E2408 randomized phase 2 trial were reviewed. Validation of the prognostic significance of PET factors identified in a previous retrospective study was performed. PET factors with a significant impact on survival outcomes were combined with significant FL International Prognostic Index 2 (FLIPI-2) factors to evaluate the predictive value of a PET-based prognostic index. Presence of ≥2 EN sites and skin/soft tissue involvement on PET were validated as predictors of overall survival. These factors were combined with all FLIPI-2 factors except "positive bone marrow biopsy" to form a PET-based prognostic score. This novel score identified a group of patients at high risk of progression of disease at 24 months. This PET-based score did not perform better than the traditional FLIPI-2 on additional analysis. Presence of ≥2 EN sites and skin/soft tissue involvement on PET predict poor outcomes in untreated FL. Further studies should be performed to determine the validity of a PET-based prognostic index in FL.

Identifiers

PMID40735350
PMCPMC12304680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.